HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Keisuke Hamada Selected Research

negamycin

1/2018Chemotherapeutics overcoming nonsense mutation-associated genetic diseases: medicinal chemistry of negamycin.
6/2015Structure-Activity Relationship Studies of 3-epi-Deoxynegamycin Derivatives as Potent Readthrough Drug Candidates.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Keisuke Hamada Research Topics

Disease

6Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker)
10/2021 - 01/2010
5Neoplasms (Cancer)
11/2021 - 03/2002
4Inborn Genetic Diseases (Disease, Hereditary)
01/2022 - 10/2014
2Obesity
05/2022 - 04/2022
2Neurodevelopmental Disorders
02/2022 - 12/2018
2Liver Diseases (Liver Disease)
02/2022 - 01/2022
1Amyloidosis
05/2022
1Metabolic Diseases (Metabolic Disease)
05/2022
1Non-alcoholic Fatty Liver Disease
04/2022
1Seizures (Absence Seizure)
02/2022
1Alcoholic Liver Diseases (Alcoholic Liver Disease)
02/2022
1Head and Neck Neoplasms (Head and Neck Cancer)
01/2022
1Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
11/2021
1Colitis
11/2021
1Muscular Dystrophies (Muscular Dystrophy)
10/2021
1Pierson syndrome
01/2021
1Neuroblastoma
01/2021
1Leukoencephalopathies
11/2011
1Epilepsy (Aura)
06/2010
1Quadriplegia (Spastic Quadriplegia)
06/2010
1Infantile Spasms (West Syndrome)
06/2010
1Genomic Instability
02/2005
1Neurofibromatosis 2 (Neurofibromatosis Type II)
03/2002

Drug/Important Bio-Agent (IBA)

5Nonsense Codon (Nonsense Mutation)IBA
01/2022 - 06/2015
3Peptides (Polypeptides)IBA
10/2021 - 01/2021
3DystrophinIBA
01/2018 - 01/2010
2EnzymesIBA
05/2022 - 02/2005
2withaferin AIBA
02/2022 - 01/2022
2Pharmaceutical PreparationsIBA
11/2021 - 10/2014
2negamycinIBA
01/2018 - 06/2015
2Anti-Bacterial Agents (Antibiotics)IBA
01/2018 - 06/2015
2Proteins (Proteins, Gene)FDA Link
01/2018 - 01/2010
1Immune Sera (Antisera)IBA
05/2022
1XenobioticsIBA
05/2022
1Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA
05/2022
1Extracellular Matrix ProteinsIBA
05/2022
1Keratin-5 (Keratin 5)IBA
05/2022
1Amyloid (Amyloid Fibrils)IBA
05/2022
1Cytochrome P-450 Enzyme System (Cytochrome P450)IBA
05/2022
1PPAR alphaIBA
05/2022
1Fibroblast Growth Factors (Fibroblast Growth Factor)IBA
05/2022
1Keratins (Keratin)IBA
05/2022
1Cytochrome P-450 CYP2E1 (CYP2E1)IBA
05/2022
1CholesterolIBA
04/2022
1LuciferasesIBA
04/2022
1FructoseIBA
04/2022
1Fatty Acids (Saturated Fatty Acids)IBA
04/2022
1Fatty Acid-Binding ProteinsIBA
04/2022
1Peroxisome Proliferator-Activated Receptors (PPAR)IBA
04/2022
1GW 6471IBA
04/2022
1Glutamic Acid (Glutamate)FDA Link
02/2022
1Carbamazepine (Tegretol)FDA LinkGeneric
02/2022
1Therapeutic UsesIBA
02/2022
1Indicators and Reagents (Reagents)IBA
01/2022
1Histones (Histone)IBA
11/2021
1Pregnane X ReceptorIBA
11/2021
1Dextrans (Dextran)FDA Link
11/2021
1sodium sulfate (sodium bisulfate)FDA LinkGeneric
11/2021
1Dystroglycans (Dystroglycan)IBA
10/2021
1Liposomes (Liposome)IBA
10/2021
1Heparin (Liquaemin)FDA LinkGeneric
01/2021
1Biological ProductsIBA
01/2021
1Laminin (Merosin)IBA
01/2021
1Amino AcidsFDA Link
10/2019
1N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA
12/2018
1DipeptidesIBA
01/2018
1EstersIBA
10/2017
1Epoxy Compounds (Epoxides)IBA
01/2016
1FD 891IBA
01/2016
1HydrazinesIBA
06/2015
1RNA Polymerase IIIIBA
11/2011
1ErbB Receptors (EGF Receptor)IBA
08/2010
1Lapatinib (GW572016)FDA Link
08/2010
1Gefitinib (Iressa)FDA Link
08/2010
1Erlotinib Hydrochloride (CP 358,774)FDA Link
08/2010
1SpectrinIBA
06/2010
1UtrophinIBA
01/2010
1Flap EndonucleasesIBA
02/2005
1Neurofibromin 2 (Merlin)IBA
03/2002

Therapy/Procedure

2Image-Guided Radiotherapy
01/2022 - 09/2020
1Particle Accelerators
01/2022